Values as of: 2024-06-26
COMMON STOCK | Drug Manufacturers - Specialty & Generic |
Last Closing
USD 1521.15Change
+15.95 (+1.06)%Market Cap
USD 3,520.42BVolume
2.56MVerdict
Verdict
Currency: INR
Country : India
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| DIVISLAB:NSE | Divi's Laboratories Limited |
N/A |
USD 1,220.22B |
| ZYDUSLIFE:NSE | Zydus Lifesciences Limited |
N/A |
USD 1,085.57B |
| DRREDDY:NSE | Dr. Reddy's Laboratories Limit.. |
N/A |
USD 1,066.25B |
| TORNTPHARM:NSE | Torrent Pharmaceuticals Limite.. |
N/A |
USD 958.22B |
| MANKIND:NSE | Mankind Pharma Ltd |
N/A |
USD 877.19B |
| LUPIN:NSE | Lupin Limited |
N/A |
USD 711.68B |
| AUROPHARMA:NSE | Aurobindo Pharma Limited |
N/A |
USD 706.65B |
| ALKEM:NSE | Alkem Laboratories Limited |
N/A |
USD 596.79B |
| GLENMARK:NSE | Glenmark Pharmaceuticals Limit.. |
N/A |
USD 347.26B |
| IPCALAB:NSE | IPCA Laboratories Limited |
N/A |
USD 288.40B |
N/A
| Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 20.70% | 71% | C- | 63% | D | ||
| Dividend Return | 0.67% | 80% | B- | 54% | F | ||
| Total Return | 21.38% | 72% | C | 63% | D | ||
| Trailing 12 Months | |||||||
| Capital Gain | 48.87% | 56% | F | 55% | F | ||
| Dividend Return | 1.22% | 71% | C- | 65% | D | ||
| Total Return | 50.09% | 58% | F | 56% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 279.39% | 73% | C | 66% | D+ | ||
| Dividend Return | 10.29% | 84% | B | 71% | C- | ||
| Total Return | 289.67% | 75% | C | 67% | D+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 32.63% | 53% | F | 49% | F | ||
| Dividend Return | 33.78% | 54% | F | 49% | F | ||
| Total Return | 1.15% | 86% | B+ | 69% | C- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 18.57% | 94% | A | 91% | A- | ||
| Risk Adjusted Return | 181.85% | 99% | N/A | 100% | F | ||
| Market Capitalization | 3,520.42B | 100% | F | 99% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
